Literature DB >> 22111489

Benefits of ticagrelor debated as antiplatelet class approaches generic market.

Thomas Morrow1.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 22111489

Source DB:  PubMed          Journal:  Manag Care        ISSN： 1062-3388


× No keyword cloud information.
  2 in total

Review 1.  A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

Authors:  Wei Eric Wang; Hongyong Wang; Xukai Wang; Chunyu Zeng
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

2.  Ticagrelor (brilinta), an antiplatelet drug for acute coronary syndrome.

Authors:  Raeanne Fuller; Benjamin Chavez
Journal:  P T       Date:  2012-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.